Etoposide and antimetabolite pharmacology in patients who develop secondary acute myeloid leukemia

Leukemia
Mary V RellingC H Pui

Abstract

Etoposide, an effective agent for acute lymphoblastic leukemia (ALL), can cause secondary acute myeloid leukemia (AML) in a subset of patients. Our objectives were to determine whether patients who develop secondary AML displayed altered etoposide pharmacokinetics or other pharmacologic characteristics compared to identically treated patients who did not develop AML. Children with newly diagnosed ALL were treated according to a protocol which included etoposide 300 mg/m2 given three times over 8 days during remission induction and once every 2-4 weeks during 120 weeks of continuation therapy. Characteristic 11q23 rearrangements were documented in seven of the eight patients with AML. Etoposide clearance, time that etoposide concentrations exceeded 10 microM, etoposide or etoposide catechol area-under-the-plasma-concentration vs time curve (AUC), serum albumin, and average methotrexate concentration did not differ significantly between the two groups; thiopurine methyltransferase (TPMT) activity tended to be lower in the eight children who did vs the 23 matched control children who did not develop AML (P=0.16). Further regression analyses likewise indicated that lower TPMT activity tended to be associated with shorter onset of s...Continue Reading

Citations

Nov 4, 2005·Investigational New Drugs·Sally Coulthard, Linda Hogarth
Mar 27, 2013·Paediatric Drugs·Shahrad Rod RassekhMichael R Hayden
May 14, 2005·Pharmacology & Therapeutics·Thomas Efferth, Manfred Volm
Mar 14, 2003·Cancer Treatment Reviews·Jeffrey E Rubnitz, Ching-Hon Pui
Jan 31, 2002·Journal of Chromatography. B, Biomedical Sciences and Applications·C L ChenF M Uckun
May 21, 2011·Biochemistry·David A JacobJoseph E Deweese
Feb 24, 2006·Nature Reviews. Cancer·Meyling H Cheok, William E Evans
Mar 15, 2003·Nature Reviews. Cancer·Smita Bhatia, Charles Sklar
Mar 23, 2002·The Pharmacogenomics Journal·S A Coulthard, A G Hall
Apr 16, 2002·Current Problems in Pediatric and Adolescent Health Care·Ka Wah Chan
Dec 2, 1999·Journal of the National Cancer Institute·M V RellingW E Evans
Jan 5, 2006·Journal of the National Cancer Institute·Lois B TravisMark H Greene
Feb 25, 2000·Current Opinion in Oncology·C H Pui
Mar 7, 2002·Journal of Pediatric Hematology/oncology·C H Pui
Nov 19, 2004·Current Opinion in Hematology·Parinda A Mehta, Stella M Davies
Jun 7, 2006·Current Opinion in Hematology·Leo Kager, William E Evans
Nov 30, 2006·Current Opinion in Gastroenterology·Irfan M HisamuddinVincent W Yang
May 11, 2012·Current Opinion in Gastroenterology·Benjamin L CohenJean-Frédéric Colombel
Nov 8, 2008·Journal of Pediatric Hematology/oncology·Marie Louise DavidsenKjeld Schmiegelow
May 20, 1999·Annual Review of Pharmacology and Toxicology·R M WeinshilboumC L Szumlanski
Mar 27, 2001·Annual Review of Pharmacology and Toxicology·H L McLeod, W E Evans
Jan 13, 2006·Annual Review of Pharmacology and Toxicology·Meyling H CheokWilliam E Evans
Dec 17, 2005·The Journal of Clinical Investigation·Shinichiro NakadaShuki Mizutani
Apr 23, 2002·Pharmacogenomics·Howard L McLeod, Chokkalingam Siva
Jan 20, 2005·Clinical Pharmacokinetics·Tony Antoniou, Alice L Tseng
Aug 16, 2013·World Journal of Gastroenterology : WJG·María Gómez-GarcíaEduardo Redondo-Cerezo
Apr 15, 2014·Leukemia·L M MortonE A Engels
Nov 6, 2007·Pharmacogenomics·Anwar HusainDavid W Hein
Oct 28, 1998·Proceedings of the National Academy of Sciences of the United States of America·C A FelixT R Rebbeck
Aug 30, 2001·Proceedings of the National Academy of Sciences of the United States of America·J G BlancoM V Relling
Apr 12, 2000·Proceedings of the National Academy of Sciences of the United States of America·R StrickJ D Rowley
Jun 10, 2000·British Journal of Haematology·C H Pui, M V Relling
May 8, 2001·Medical and Pediatric Oncology·C A Felix
May 18, 1999·Pediatric Hematology and Oncology·C A Felix, J Blatt

❮ Previous
Next ❯

Related Concepts

Related Feeds

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.